April 2017

09 Apr

47

Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH

In All

​​C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab. Louisville, Ky. – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…

05 Apr

31

Enterprise Therapeutics Receives Funding from Cystic Fibrosis Trust

In All, Portfolio

Brighton, UK, April 5, 2017 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has won funding from the Cystic Fibrosis Trust to identify new drug mechanisms for the treatment of cystic…

04 Apr

29

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

In All, Portfolio

Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately. Paul Sekhri is currently CEO and President of the US…